- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02861365
Myocardial Perfusion and Scarring in Adults With Congenital Heart Disease
Quantitative Myocardial Perfusion, Myocardial Scarring and Their Contribution to Late Clinical Decompensation in Adults With Congenital Heart Disease
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Children's National Health System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subjects 18 years of age or older
- All defects that have a right ventricle that supports the systemic circulation
- All defects with a functional single ventricle
- Written informed consent
Exclusion Criteria:
Subjects with a contraindication to magnetic resonance imaging (MRI) scanning will be excluded. These contraindications include subjects with the following devices:
- Central nervous system aneurysm clips
- Implanted neural stimulator
- Implanted cardiac pacemaker or defibrillator
- Cochlear implant
- Ocular foreign body (e.g. metal shavings)
- Implanted Insulin pump
- Metal shrapnel or bullet
- Severe heart damage that makes it difficult to breathe while lying flat
- Pregnant women (Women of childbearing potential who are uncertain as to whether they are pregnant will be required to have a screening urine or blood pregnancy test)
- Subjects with active symptoms of myocardial ischemia occurring despite maximally tolerated doses of oral antianginal therapy and intravenous nitroglycerin
Furthermore, the following subject groups will be excluded from studies involving the administration of MRI contrast agents:
- lactating women unless they are willing to discard breast milk for 24 hours after receiving gadolinium
- renal disease (estimated glomerular filtration rate [eGFR] < 30 ml/min/1.73 m2 body surface area)
The eGFR will be used to estimate renal function if reported by the laboratory. Otherwise, estimated glomerular filtration rate (eGFR) can be based on the Modification of Diet in Renal Disease (MDRD) study equation (see below) in subjects with stable renal function. This formula is not applicable to subjects with acute renal insufficiency:
eGFR (ml/min/1.73 m2) = 175 x (serum creatinine)-1.154 x (age)-0.203 x 0.742 (if the subject is female) x 1.212 (if the subject is black)
Additional Exclusion Criteria for Vasodilator Stress MRI:
- Myocardial infarction within 24 hours
- Uncontrolled heart failure
- Uncontrolled asthma or emphysema
- Ventricular arrhythmia (sustained ventricular arrhythmia at the time of MR scan)
- Second degree heart block or higher
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Myocardial Ischemia measuring coronary perfusion reserve.
Time Frame: 5 years
|
Compare quantitative myocardial perfusion at stress and rest with measures of systolic and diastolic function in exams performed in close temporal proximity.
|
5 years
|
Myocardial Ischemia measuring ejection fraction.
Time Frame: 5 years
|
Compare the extent of myocardial ischemia through ejection fraction measurement of the systemic ventricle.
|
5 years
|
Myocardial Ischemia measuring heart inflow Doppler.
Time Frame: 5 years
|
Compare heart inflow Doppler of the systemic atrioventricular valve to understand the extent of myocardial ischemia.
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Scarring and fibrosis by measuring Late Gadolinium Enhancement results.
Time Frame: 5 years
|
Directly compare the extent of myocardial scarring/fibrosis with echo-derived measures of systolic and diastolic function.
|
5 years
|
Scarring and fibrosis by measuring systolic and diastolic function.
Time Frame: 5 years
|
Compare the extent of myocardial scarring/fibrosis with echo-derived measures of systolic and diastolic function.
|
5 years
|
Comparison of MRI measurements with blood test.
Time Frame: 5 years
|
Number of participants with predictable future heart failure symptom will be assessed by comparing all cardiac MRI exam measurements with blood test.
|
5 years
|
Comparison of MRI measurements with walk test.
Time Frame: 5 years
|
Number of participants with predictable future heart failure symptom will be assessed by comparing all cardiac MRI exam measurements with walk test.
|
5 years
|
Comparison of MRI measurements with NY Heart Association class
Time Frame: 5 years
|
Number of participants with predictable future heart failure symptom will be assessed by comparing all cardiac MRI exam measurements with NY Heart Association class.
|
5 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Laura Olivieri, MD, Children's National Health Systems
Publications and helpful links
General Publications
- Verheugt CL, Uiterwaal CS, van der Velde ET, Meijboom FJ, Pieper PG, van Dijk AP, Vliegen HW, Grobbee DE, Mulder BJ. Mortality in adult congenital heart disease. Eur Heart J. 2010 May;31(10):1220-9. doi: 10.1093/eurheartj/ehq032. Epub 2010 Mar 5.
- Rutledge JM, Nihill MR, Fraser CD, Smith OE, McMahon CJ, Bezold LI. Outcome of 121 patients with congenitally corrected transposition of the great arteries. Pediatr Cardiol. 2002 Mar-Apr;23(2):137-45. doi: 10.1007/s00246-001-0037-8. Epub 2002 Feb 19.
- Meijboom F, Szatmari A, Deckers JW, Utens EM, Roelandt JR, Bos E, Hess J. Long-term follow-up (10 to 17 years) after Mustard repair for transposition of the great arteries. J Thorac Cardiovasc Surg. 1996 Jun;111(6):1158-68. doi: 10.1016/s0022-5223(96)70217-9.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00003067
- contract (Other Identifier: NIH)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- CSR
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiac Disease
-
University of British ColumbiaRecruitingSurgery | Cardiac Event | Cardiac Disease | Cardiac Complication | Cardiac Valve Disease | Surgery-ComplicationsCanada
-
Istituto Auxologico ItalianoRecruitingCardiovascular Diseases | Cardiomyopathies | Ischemic Heart Disease | Sudden Cardiac Death Due to Cardiac ArrhythmiaItaly
-
Ostfold University CollegeNot yet recruitingCardiac Arrest | Cardiac Arrhythmia | Cardiac Disease | Cardiac Death
-
Johns Hopkins UniversityNational Human Genome Research Institute (NHGRI)Enrolling by invitationGenetic Counseling | Inherited Cardiac DiseaseUnited States
-
Centro Medico TeknonRecruitingMyocardial Infarction | Ischemic Heart Disease | Ventricular Tachycardia | Magnetic Resonance Imaging | Ventricular Arrythmia | Sudden Cardiac Death | Sudden Cardiac Death Due to Cardiac ArrhythmiaSpain
-
Children's Healthcare of AtlantaTerminated
-
Beijing Chao Yang HospitalBeijing Boren Hospital; Beijing Chuiyangliu HospitalNot yet recruitingM-protein Related Cardiac Disease
-
Maastricht University Medical CenterActive, not recruitingHeart Diseases | Cardiac Conduction DefectNetherlands
-
Vanderbilt University Medical CenterCompletedCardiac DiseasesUnited States
-
St. Luke's-Roosevelt Hospital CenterCompleted